Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer [0.03%]
纳米载体与耐药肿瘤的相互作用：对抗癌症药物抗性的新方法
Aleksandra Benko,David Medina-Cruz,Ada Vernet-Crua et al.
Aleksandra Benko et al.
Cancer is one of the biggest healthcare concerns in our century, a disease whose treatment has become even more difficult following reports of drug-resistant tumors. When this happens, chemotherapy treatments fail or decrease in efficiency,...
The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance [0.03%]
泛素连接酶在卵巢癌化疗耐药中的作用研究进展
Yang Meng,Lei Qiu,Su Zhang et al.
Yang Meng et al.
Epithelial cancer of the ovary exhibits the highest mortality rate of all gynecological malignancies in women today, since the disease is often diagnosed in advanced stages. While the treatment of cancer with specific chemical agents or dru...
A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma [0.03%]
弥漫性大B细胞淋巴瘤和多发性骨髓瘤中的苯达莫司汀耐药基因特征
Issa Ismail Issa,Rasmus Froberg Brøndum,Hanne Due et al.
Issa Ismail Issa et al.
Aim: Bendamustine is primarily used for treatment of indolent lymphomas but has shown efficacy in some patients with diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Molecular-based patient stratification for identification ...
Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer [0.03%]
天然产物在克服膀胱癌顺铂化学抗性方面的作用
Ganeshkumar Rajendran,John A Taylor rd,Benjamin L Woolbright
Ganeshkumar Rajendran
Cisplatin remains an integral part of the treatment for muscle invasive bladder cancer. A large number of patients do not respond to cisplatin-based chemotherapy and efficacious salvage regimens are limited. Immunotherapy has offered a seco...
Evaluation of the reducing potential of PSMA-containing endosomes by FRET imaging [0.03%]
利用FRET成像技术评估PSMA阳性囊泡的还原潜能
Chelvam Venkatesh,Jiayin Shen,Karson S Putt et al.
Chelvam Venkatesh et al.
Aim: Ligand-targeted therapeutics are experiencing increasing use for treatment of human diseases due to their ability to concentrate a desired drug at a pathologic site while reducing accumulation in healthy tissues. For many ligand-target...
Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer [0.03%]
代谢重新编程作为前列腺癌内分泌治疗耐药的新兴机制
Paolo Chetta,Giorgia Zadra
Paolo Chetta
Prostate cancer (PCa) is the second leading cause of cancer-related death in the US. Androgen receptor (AR) signaling is the driver of both PCa development and progression and, thus, the major target of current in-use therapies. However, de...
Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells [0.03%]
获得性耐药非小细胞肺癌细胞的特征化研究
Christophe Deben,Laurie Freire Boullosa,Andreas Domen et al.
Christophe Deben et al.
Aim: The purpose of this manuscript is to study the potential characteristics of acquired nutlin-3 resistant non-small cell lung cancer cells (NSCLC). Nutlin-3 is an inhibitor of the murine-double minute 2 protein, the main negative regulat...
Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance [0.03%]
基于白蛋白的纳米载体克服阿霉素耐药性的新思路
Federica Bessone,Chiara Dianzani,Monica Argenziano et al.
Federica Bessone et al.
Aim: Resistance to chemotherapy is a major limiting factor that hamper the effectiveness of anticancer therapies. Doxorubicin is an antineoplastic agent used in the treatment of a wide range of cancers. However, it presents several limitati...
The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas [0.03%]
胶质母细胞瘤治疗耐药获得中外泌体的作用
Anudeep Yekula,Abigail Taylor,Alexandra Beecroft et al.
Anudeep Yekula et al.
Glioblastoma (GBM) is the most aggressive primary brain tumor with a median survival of 15 months despite standard care therapy consisting of maximal surgical debulking, followed by radiation therapy with concurrent and adjuvant temozolomid...
Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics [0.03%]
纳米载体给药系统在临床克服癌症药物耐药方面的展望
Anna Ulldemolins,Joaquin Seras-Franzoso,Fernanda Andrade et al.
Anna Ulldemolins et al.
Advanced cancer is still considered an incurable disease because of its metastatic spread to distal organs and progressive gain of chemoresistance. Even though considerable treatment progress and more effective therapies have been achieved ...